About 100 reports

  • TUBERCULOSIS, PNEUMONIA, MRSA, SEPSIS, GLOBAL, PIPELINES BY MOLECULAR TARGET, 2017
  • 4.2.2 MRSA

Acquired Antibiotic Resistance Genes: An Overview.

  • Anti-Infective
  • Antibiotic Resistance
  • Infectious Disease
  • World
  • Deals & Alliance
  • DEVELOPMENT OF ANTIBIOTIC RESISTANCE
  • SPREAD OF ANTIBIOTIC RESISTANCE
  • Antibiotic Resistance
  • Allergan plc
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • RISING GOVERNMENT INITIATIVES TO COMBAT ANTIBIOTIC RESISTANCE
  • Rising government initiatives to combat antibiotic resistance
  • Antibiotic Resistance
  • Forecast
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • ALGORITHM - BACTERIAL ANTIBIOTIC RESISTANCE
  • ALGORITHM - BACTERIAL ANTIBIOTIC RESISTANCE PRODUCT OVERVIEW
  • Antibiotic Resistance
  • Healthcare
  • Infection Control
  • United States
  • OpGen, Inc.
  • APR 12, 2017: OPGEN TO PRESENT ANTIBIOTIC RESISTANCE PREDICTION DATA AT 25TH EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (ECCMID)
  • OPGEN RAISES USD10 MILLION IN PUBLIC OFFERING OF UNITS
  • Antibiotic Resistance
  • United States
  • Company
  • Demand
  • OpGen, Inc.
  • OCT 06, 2016: PENN MEDICINE RECEIVES CDC AWARD TO COMBAT ANTIBIOTIC RESISTANCE
  • JUL 27, 2016: CDC FUNDING ACCELERATES ANTIBIOTIC RESISTANCE EFFORTS
  • Antibiotic Resistance
  • Infectious Disease
  • Vaccine
  • United States
  • GlobalData's company
  • May 10, 2017: Bausch + Lomb Reports Updated Results of the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) Study
  • May 04, 2016: Bausch + Lomb Reports Preliminary 2015 Results of the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Study
  • Antibiotic Resistance
  • Eye Disease
  • Ophthalmology
  • United States
  • Bausch & Lomb Incorporated
  • Apr 06, 2017: Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing
  • Antibiotic Resistance
  • Medical Equipment
  • Germany
  • United States
  • Curetis N.V.
  • 12.3.4 Antibiotic Resistance Patterns
  • ILLUSTRATION DEPICTING THE KEY MECHANISMS OF ANTIBIOTIC RESISTANCE OBSERVED IN GRAM-
  • Antibiotic Resistance
  • Achaogen, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • The Medicines Company
  • Oct 06, 2016: Synthetic Biologics Awarded Research Contract from Centers for Disease Control and Prevention (CDC) for Microbiome Assessment and Intervention to Address Antibiotic Resistance
  • Antibiotic Resistance
  • Digestive System Disorder
  • United States
  • Product Initiative
  • Synthetic Biologics
  • OPGEN RAISES USD10 MILLION IN PUBLIC OFFERING OF UNITS
  • JAN 26, 2017: OPGEN REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS

Announced collaboration with Merck to develop novel rapid diagnostics and informatics tools to combat antibiotic resistance.

  • Antibiotic Resistance
  • United States
  • Company
  • Demand
  • OpGen, Inc.
  • ACCELERATE DIAGNOSTICS: COMPANY SNAPSHOT
  • Product Approvals

This AR Lab Network supports the nationwide lab capacity to rapidly detect antibiotic resistance and further inform local responses to prevent the spread and protect people from antibiotic resistance.

  • Anti-Infective
  • Antibiotic Resistance
  • In Vitro Diagnostic Reagent
  • In Vitro Diagnostics
  • Thermo Fisher Scientific, Inc.
  • 4.6.9 CONCLUSION
  • 2.7.2 MRSA

Antibiotic resistance genes have allowed bacteria to become capable of developing resistance to antibiotics through several mechanisms.

  • Antibiotic Resistance
  • World
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • JUN 05, 2015: TAXIS PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING POTENTIAL VIABILITY OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE
  • APR 27, 2015: TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE
  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • JUN 05, 2015: TAXIS PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING POTENTIAL VIABILITY OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE
  • APR 27, 2015: TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE
  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • ANTIBIOTIC RESISTANCE MARKER CARTRIDGE
  • Antibiotic Resistance Marker Cartridge - Product Status
  • Antibiotic Resistance
  • China
  • Europe
  • United States
  • Curetis N.V.
  • MOUNTING THREAT OF MICROBIAL ANTIBIOTIC RESISTANCE
  • SELECTED ANTIBIOTIC RESISTANCE FACTS (CDC)
  • Antibiotic Resistance
  • United States
  • Alere Inc.
  • Cepheid
  • Roche Group
  • and study to combat antibiotic resistance
  • AMR
  • Anti-Infective
  • Antibiotic Resistance
  • Pharmaceutical
  • Therapy
  • United States
  • Resistance to antibiotics is a major challenge. Finding out different alternatives to direct killing of antimicrobials, approaches for discovery of combination antibiotics might overcome this challenge.
  • 7.3.3 FRANCE
  • Antibiotic Resistance
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • ATLAS IO SYSTEM - BACTERIAL IDENTIFICATION AND ANTIBIOTIC RESISTANCE
  • ATLAS IO SYSTEM - BACTERIAL IDENTIFICATION AND ANTIBIOTIC RESISTANCE - PRODUCT STATUS
  • Antibiotic Resistance
  • Sexually Transmitted Disease
  • United Kingdom
  • United States
  • GlobalData's company

Tetraphase Pharmaceuticals Inc (Tetraphase) is a clinical stage life science company that discovers and develops antibiotic resistance medicines.

  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Soligenix, Inc.
  • TOSATOXUMAB - DRUG PROFILE

The ERS notes that antibiotic resistance is one of the major threats undermining the treatment of respiratory infections.

  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Cempra, Inc.
  • ALENA SYSTEM - ANTIBIOTIC RESISTANCE
  • ALENA System - Antibiotic Resistance - Product Description
  • Antibiotic Resistance
  • Biomarker
  • Molecular Diagnostic
  • United States
  • Axela, Inc.
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones

" The figures highlighted in Jim O' Neill' s report - and in particular the potential human cost of not addressing antibiotic resistance - are significant.

  • Anti-Infective
  • Antibiotic Resistance
  • World
  • Product Initiative
  • MGB Biopharma Limited

This approach is less susceptible to development of antibiotic resistance, can be used both therapeutically and prophylactically.

  • Antibiotic Resistance
  • Infectious Disease
  • United States
  • World
  • Product Initiative
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones

" The figures highlighted in Jim O' Neill' s report - and in particular the potential human cost of not addressing antibiotic resistance - are significant.

  • Antibiotic Resistance
  • United Kingdom
  • World
  • Product Initiative
  • MGB Biopharma Limited
  • ANTIBIOTIC RESISTANCE
  • ANTIBIOTIC RESISTANCE PREVENTION
  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • World
  • Company
  • SELECTED COMPANIES MARKETING PCR/NAAT-BASED ANTIBIOTIC RESISTANCE/SUSCEPTIBILITY TESTS
  • SELECTED COMPANIES MARKETING PCR/NAAT SYNDROMIC TESTS/PANELS FOR INFECTIOUS DISEASES
  • Antibiotic Resistance
  • Molecular Diagnostic
  • United States
  • World
  • Biocartis S.A.
  • KEY MILESTONES FOR EMERGENCE OF ANTIBIOTIC RESISTANCE
  • LACTAMASE MEDIATED ANTIBIOTIC RESISTANCE IN MRSA
  • Antibiotic Resistance
  • Cempra, Inc.
  • CyDex Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.
  • Merck & Co., Inc.
  • Feb 23, 2017: Accelerate Diagnostics Receives FDA Marketing Authorization for the Accelerate Pheno System

The faster we can tailor therapy, the better things are for the patient and the potential prevention of antibiotic resistance. "

  • Antibiotic Resistance
  • United States
  • Company
  • Product Initiative
  • Accelerate Diagnostics, Inc.